Abstract
Human health in urban environment has emerged as a primary focus of sustainable development during the time of global pandemic caused by a severe acute respiratory syndrome due to the SARS-CoV-2 coronavirus, COVID-19. It has reshaped the world with the way our communities interact, people work, commute, and spend their leisure time. While different mitigation solutions for controlling COVID-19 virus transmission have already been established, global models that would explain and predict the impact of urban environments on the case fatality ratio CFR of COVID-19 (defined as the number of deaths divided by the number of cases over a time window) are missing. Here, with readily available data from public sources, we study the CFR of the coronavirus for 118 locations (city zip-codes, city boroughs, and cities) worldwide to identify the links between the CFR and outdoor, indoor and personal urban factors. We show that a probabilistic model, optimized on the sample of 20 districts from 4 major US cities, provides an accurate predictive tool for the CFR of COVID-19 regardless of the geographical location. When adjusted for the population, our model can be used to evaluate risk and severity of the disease at multi-geospatial scales worldwide ranging from zip-codes and neighborhoods to cities and countries for different waves of the pandemic. Our results suggest that although disease screening and vaccination policies to containment and lockdowns remain critical in controlling the spread of airborne diseases, urban factors such as population density, humidity, or order of buildings, should all be taken into consideration when identifying resources and planning targeted responses to mitigate the impact and severity of the viruses transmitted through air. We advocate the study of urban factors as a path towards facilitating timely deployment of targeted countermeasures and confinement strategies where sharing of personal information and availability of tests may be restricted or limited.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge CNRS-Innovation for the SURe project funding (www.sure-tech.fr) through the pre-maturation and RISE programs.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
COVID-19 cases and deaths data: http://publichealth.lacounty.gov/media/Coronavirus/locations.htm https://www1.nyc.gov/site/doh/covid/covid-19-data-totals.page https://opendata.dc.gov/datasets/DCGIS::dc-covid-19-cases-by-ward/about https://data.cityofchicago.org/Health-Human-Services/COVID-19-Cases-Tests-and-Deaths-by-ZIP-Code/yhhz-zm2v https://kingcounty.gov/depts/health/covid-19/data/daily-summary.aspx https://www.boston.gov/news/coronavirus-disease-covid-19-boston https://www.denvergov.org/Government/COVID-19-Information/COVID-19-in-Denver/COVID-19-Case-Dashboards https://sf.gov/data/covid-19-cases-and-deaths https://www.health.pa.gov/topics/disease/coronavirus/Pages/Coronavirus.aspx https://data.london.gov.uk/dataset/coronavirus--covid-19--cases https://coronavirus.data.gov.uk/ https://www.berlin.de/corona/lagebericht/#barrierefreiheit https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/situacionActual.htm https://www.comunidad.madrid/servicios/salud/coronavirus#situacion-epidemiologica-actual https://covid.saude.gov.br/ http://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx https://www.mygov.in/covid-19 https://www.worldometers.info/coronavirus/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript and supplementary information (SI) with url links in SI figures to access publicly available raw data.
